The European Commission Research and Innovation Directorate published a report it had commissioned to evaluate the role and impact of the European Union’s (EU) Research Framework Programme activities in the field of Poverty-Related and Neglected Diseases (PRNDs).

VAC2VAC is pleased to announce that one year after its start it has already created enough interest to have the Medicines Evaluation Board (MEB), a regulatory agency and an independent administrative body residing under the Government of the Netherlands, joining its membership.

During the first year of the VAC2VAC project ample of process has been made. Here you can find a two page summary of the progress.

The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.

“Four years of European research on the development of universal influenza vaccines: what have we learnt, and how can we move forward?”

The EDUFLUVAC partners, as part of their work programme on the development of a broadly reactive influenza vaccine, are planning a workshop in close collaboration with the FLUTCORE and UNISEC consortia entitled: “Four years of European research on the development of universal influenza vaccines: what have we learnt and how can we move forward?”.

The workshop will be held in Brussels, Belgium on 12-14 June 2017

World Malaria Day is a chance to shine a spotlight on the global effort to control malaria. Each year on April 25, Roll Back Malaria (RBM) partner organizations unite around a common World Malaria Day theme.

A meeting report summarising the outcome of the EDUFLUVAC workshop on “Immunoassay standardisation for universal influenza vaccines” was recently published on Influenza and Other Respiratory Viruses journal.

The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called “universal” influenza vaccines, and to explore a path towards the standardisation of such assays.  To address this critical topic, a workshop on “Immunoassay standardisation for universal influenza vaccines” was co-organised in June 2015 by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health / National Institute of Allergy and Infectious Diseases, USA. 

The workshop agenda encompassed a wide range of immunoassays that can be used to assess immune responses to broadly reactive influenza vaccines, from classical serological assays to assays measuring cell mediated immunity.  The workshop audience agreed that it was not possible to establish one universal immunoassay for universal influenza vaccine(s) because the approaches towards these vaccines differ significantly in their nature and immunogenicity properties.  Therefore, different scientific rationales for the choice of the immunoassay selection are required for the development of different universal influenza vaccines.  The meeting agreed that standardisation of the immunoassays is an important goal but that there is a long way to go.  A clear need for more collaboration on harmonisation of immunoassays was identified and the European - American partnership established during the organisation of this workshop was recognised as a clear asset in this direction and will be sustained.